Jazz Pharmaceuticals (JAZZ) Income from Continuing Operations (2010 - 2026)

Jazz Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 293100000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 418.59% year-over-year to 293100000.0 in Q1 2026; TTM through Mar 2026 was 29695000.0, a 93.85% decrease from a year earlier, with the FY2025 full-year figure at 355416000.0, down 163.27% from the prior year.
• Income from Continuing Operations rose to 293100000.0 in Q1 2026 per JAZZ's latest filing, from 203514000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 293100000.0 in Q1 2026 and bottomed at 718354000.0 in Q2 2025.
• The 5-year median for Income from Continuing Operations is 94626000.0 (2023), against an average of 41365529.41.
• Across the five-year window, Income from Continuing Operations slumped 641.44% in 2022 and soared 1116.53% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 239951000.0 in 2022, then soared by 139.44% to 94626000.0 in 2023, then surged by 102.0% to 191148000.0 in 2024, then climbed by 6.47% to 203514000.0 in 2025, then jumped by 44.02% to 293100000.0 in 2026.
• Per Business Quant, the three latest JAZZ Income from Continuing Operations figures stand at 293100000.0 (Q1 2026), 203514000.0 (Q4 2025), and 251435000.0 (Q3 2025).